en · de · es
nad-notes.peptides6155.com › Blog › Sr9009 Background And Mechanism — 2026 Update

Sr9009 Background And Mechanism — 2026 Update

By Editorial Desk · published 2025-08-07 · last reviewed 2025-09-26 · Blog

certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Related pages on this site

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

SR9009 Handling and Quality Control

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Reference notes

The Ground Forces possess various domestic and foreign weapons and computer systems. Some equipment is from the United States, modified for IDF use, such as the M4A1 and M16 assault rifles, the M24 SWS 7.62 mm bolt action sniper rifle, the SR-25 7.62 mm semi-automatic sniper rifle, and the AH-1 Cobra and AH-64D Apache attack helicopters. Israel has a domestic arms industry, which has developed weapons and vehicles such as the Merkava battle tank series, and various small arms such as the Galil and Tavor assault rifles, and the Uzi submachine gun.

Honokiol is a lignan isolated from the bark, seed cones, and leaves of trees belonging to the genus Magnolia. It has been identified as one of the chemical compounds in some traditional Eastern herbal medicines along with magnolol, 4-O-methylhonokiol, and obovatol. Honokiol, a compound with a spicy odor extracted from various Magnolia species worldwide, including those native to the Southeastern United States and Mexico, can readily cross the blood-brain and cerebrospinal fluid barriers, making it a highly bioavailable and potentially effective therapeutic agent. Honokiol is a small, hydrophobic neolignan biphenol structurally similar to propofol that can be purified efficiently from its isomer magnolol using advanced chromatography techniques such as magnolol acetonide protection followed by flash chromatography or high-capacity high-speed countercurrent chromatography. Extracts from the bark and seed cones of Magnolia trees have been traditionally used in Chinese, Korean, and Japanese medicine as analgesics and treatments for anxiety and mood disorders, notably in formulas like Houpu in Chinese medicine and Kampo in Japan. Honokiol is a pleiotropic natural compound under preliminary research for antitumor, anti-inflammatory, antioxidant, neuroprotective, and antithrombotic properties, showing therapeutic potential across the central nervous system, cardiovascular system, and gastrointestinal system, though it may pose bleeding risks in patients with hemophilia, Von Willebrand disease, or those on anticoagulant therapy.

=== Pharmacokinetics === The time that it takes for serum concentrations of clinafloxacin to reach the maximum concentration (Cmax) in healthy volunteers after taking a dose by mouth is 0.7 hours. The elimination half-life in humans is 6.1 hours. Steady state levels of clinafloxacin are achieved in 3 days of twice daily dosing by mouth in healthy volunteers. About half of an administered clinafloxacin dose is found unchanged in the urine, meaning that the drug is cleared from the blood stream roughly equally by hepatic metabolism (liver-induced degradation) and renal elimination (kidney-mediated removal).

Division of analytical chemistry and laboratory of bio-electrochemical biosensor research function in this department. The division conducts research in the area of methods of electrochemical analysis using chemically modified electrodes and biosensors. The head of the department is Professor Gennady A. Evtyugin, doctor of Science in chemistry. The Department conducts research in the following fields:

Valence 3 is dominant in all subsequent elements up to lawrencium (with the exception of nobelium). Curium can be tetravalent in solids (fluoride, dioxide). Berkelium, along with a valence of +3, also shows the valence of +4, more stable than that of curium; the valence 4 is observed in solid fluoride and dioxide. The stability of Bk4+ in aqueous solution is close to that of Ce4+. Only valence 3 was observed for californium, einsteinium and fermium. The divalent state is proven for mendelevium and nobelium, and in nobelium it is more stable than the trivalent state. Lawrencium shows valence 3 both in solutions and solids. The redox potential

Sources: en.wikipedia.org

Reference notes

The MMR vaccine as a cause of autism is one of the most extensively debated hypotheses regarding the origins of autism. Andrew Wakefield et al. reported a study of 12 children who had autism and bowel symptoms, in some cases reportedly with onset after MMR. Although the paper, which was later retracted by the journal, concluded that there was no association between the MMR vaccine and autism, Wakefield nevertheless suggested a false notion during a 1998 press conference that giving children the vaccines in three separate doses would be safer than a single dose. Administering the vaccines in three separate doses does not reduce the chance of adverse effects, and it increases the opportunity for infection by the two diseases not immunized against first. In 2004, the interpretation of a causal link between MMR vaccine and autism was formally retracted by ten of Wakefield's twelve co-authors. The retraction followed an investigation by The Sunday Times, which stated that Wakefield "acted dishonestly and irresponsibly". The Centers for Disease Control and Prevention, the Institute of Medicine of the National Academy of Sciences, and the U.K. National Health Service have all concluded that there is no evidence of a link between the MMR vaccine and autism. In February 2010, The Lancet, which published Wakefield's study, fully retracted it after an independent auditor found the study to be flawed. In January 2011, an investigation published in the journal BMJ described the Wakefield study as the result of deliberate fraud and manipulation of data.

His first tournament brought immediate reward. Colombia went through the group stage of the 1987 Copa América unbeaten, lost 2–1 to Chile in the semi-final, then beat the hosts Argentina 2–1 at the Monumental on 11 July through Gabriel Jaime Gómez and John Jairo Galeano, Claudio Caniggia replying late before 15,000 spectators. Arnoldo Iguarán finished as the tournament's leading scorer with four goals. The revival coincided with an influx of narcotics money into the domestic game. Atlético Nacional, funded through the Medellín Cartel and its leader Pablo Escobar, retained Colombian internationals who would otherwise have moved abroad and recruited foreign players the league could not previously afford; Maturana, who managed the club from 1987 to 1990, later acknowledged that "the introduction of drug money into soccer allowed us to bring in great foreign players. It also kept our best players from leaving. Our level of play took off." On 31 May 1989 Nacional, fielding Higuita, Andrés Escobar, Leonel Álvarez and Albeiro Usuriaga, beat Olimpia 5–4 on penalties at El Campín to become the first Colombian club to win the Copa Libertadores, supplying Maturana with a ready-made international spine. Colombia were eliminated in the group stage of the 1989 Copa América in Brazil, a 1–0 loss to Paraguay proving decisive despite a goalless draw with the eventual champions. The World Cup qualifiers opened a fortnight later.

==== Biomarkers of exposure ==== Several tests can determine exposure to benzene. Benzene itself can be measured in breath, blood, or urine, however such testing is usually limited to the first 24 hours post-exposure due to the relatively rapid removal of the chemical by exhalation or biotransformation. The majority of people in developed countries have measureable baseline levels of benzene and other aromatic petroleum hydrocarbons in their blood. In the body, benzene is enzymatically converted to a series of oxidation products including muconic acid, phenylmercapturic acid, phenol, catechol, hydroquinone and 1,2,4-trihydroxybenzene. Most of these metabolites have some value as biomarkers of human exposure, since they accumulate in the urine in proportion to the extent and duration of exposure, and they may still be present for some days after exposure has ceased. The current ACGIH biological exposure limits for occupational exposure are 500 μg/g creatinine for muconic acid and 25 μg/g creatinine for phenylmercapturic acid in an end-of-shift urine specimen.

He went on to graduate school at the California Institute of Technology (Caltech) in Pasadena, California, under the guidance of Roscoe Dickinson and Richard Tolman. His graduate research involved the use of X-ray diffraction to determine the structure of crystals. He published seven papers on the crystal structure of minerals while he was at Caltech. He received his PhD in physical chemistry and mathematical physics, summa cum laude, in 1925.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network